FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2791640892> ?p ?o ?g. }

• W2791640892 endingPage "136" @default.
• W2791640892 startingPage "130" @default.
• W2791640892 abstract "Sacubitril/valsartan is an angiotensin receptor–neprilysin inhibitor indicated for the treatment of patients with chronic heart failure (HF) with reduced ejection fraction; however, its mechanism of benefit remains unclear. Biomarkers that are linked to ventricular remodeling, myocardial injury, and fibrosis may provide mechanistic insight and important clinical guidance regarding sacubitril/valsartan use. This 52-week, multicenter, open-label, single-arm study is designed to (1) correlate biomarker changes with cardiac remodeling parameters, cardiovascular outcomes, and patient-reported outcome data and (2) determine short- and long-term changes in concentrations of biomarkers related to potential mechanisms of action and effects of sacubitril/valsartan therapy. Approximately 830 patients with HF with reduced ejection fraction will be initiated and titrated on sacubitril/valsartan according to United States prescribing information. Primary efficacy end points include the changes in N-terminal pro–B-type natriuretic peptide concentrations and cardiac remodeling from baseline to 1 year. Secondary end points include changes in concentrations of N-terminal pro–B-type natriuretic peptide and remodeling to 6 months, and changes in patient-reported outcomes using the Kansas City Cardiomyopathy Questionnaire-23 from baseline to 1 year. In addition, several other relevant biomarkers will be measured. Biomarker changes relative to the number of cardiovascular events in 12 months will also be assessed as exploratory end points. Results from the Prospective Study of Biomarkers, Symptom Improvement, and Ventricular Remodeling During Sacubitril/Valsartan Therapy for Heart Failure (PROVE-HF) will help establish a mechanistic understanding of angiotensin receptor–neprilysin inhibitor therapeutic benefits and provide clinicians with clarity on how to interpret information on biomarkers during treatment (PROVE-HF ClinicalTrials.gov identifier: NCT02887183)." @default.
• W2791640892 created "2018-03-29" @default.
• W2791640892 creator A5007852817 @default.
• W2791640892 creator A5012641937 @default.
• W2791640892 creator A5022237859 @default.
• W2791640892 creator A5022314919 @default.
• W2791640892 creator A5043012263 @default.
• W2791640892 creator A5043064522 @default.
• W2791640892 creator A5043416120 @default.
• W2791640892 creator A5054830306 @default.
• W2791640892 creator A5063965210 @default.
• W2791640892 date "2018-05-01" @default.
• W2791640892 modified "2023-10-14" @default.
• W2791640892 title "Rationale and methods of the Prospective Study of Biomarkers, Symptom Improvement, and Ventricular Remodeling During Sacubitril/Valsartan Therapy for Heart Failure (PROVE-HF)" @default.
• W2791640892 cites W172640170 @default.
• W2791640892 cites W1972406619 @default.
• W2791640892 cites W1974113963 @default.
• W2791640892 cites W1996447756 @default.
• W2791640892 cites W2004114486 @default.
• W2791640892 cites W2008056411 @default.
• W2791640892 cites W2015370906 @default.
• W2791640892 cites W2023603860 @default.
• W2791640892 cites W2030151847 @default.
• W2791640892 cites W2031034134 @default.
• W2791640892 cites W2044591445 @default.
• W2791640892 cites W2066228805 @default.
• W2791640892 cites W2084671075 @default.
• W2791640892 cites W2087002521 @default.
• W2791640892 cites W2097123331 @default.
• W2791640892 cites W2113698123 @default.
• W2791640892 cites W2123536767 @default.
• W2791640892 cites W2128262573 @default.
• W2791640892 cites W2146070412 @default.
• W2791640892 cites W2150820056 @default.
• W2791640892 cites W2152791175 @default.
• W2791640892 cites W2165078406 @default.
• W2791640892 cites W2172046452 @default.
• W2791640892 cites W2181968881 @default.
• W2791640892 cites W2292493149 @default.
• W2791640892 cites W2363643794 @default.
• W2791640892 cites W2468095632 @default.
• W2791640892 cites W2573482863 @default.
• W2791640892 cites W2607896223 @default.
• W2791640892 cites W4238907867 @default.
• W2791640892 cites W91108901 @default.
• W2791640892 doi "https://doi.org/10.1016/j.ahj.2017.12.021" @default.
• W2791640892 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29754651" @default.
• W2791640892 hasPublicationYear "2018" @default.
• W2791640892 type Work @default.
• W2791640892 sameAs 2791640892 @default.
• W2791640892 citedByCount "61" @default.
• W2791640892 countsByYear W27916408922018 @default.
• W2791640892 countsByYear W27916408922019 @default.
• W2791640892 countsByYear W27916408922020 @default.
• W2791640892 countsByYear W27916408922021 @default.
• W2791640892 countsByYear W27916408922022 @default.
• W2791640892 countsByYear W27916408922023 @default.
• W2791640892 crossrefType "journal-article" @default.
• W2791640892 hasAuthorship W2791640892A5007852817 @default.
• W2791640892 hasAuthorship W2791640892A5012641937 @default.
• W2791640892 hasAuthorship W2791640892A5022237859 @default.
• W2791640892 hasAuthorship W2791640892A5022314919 @default.
• W2791640892 hasAuthorship W2791640892A5043012263 @default.
• W2791640892 hasAuthorship W2791640892A5043064522 @default.
• W2791640892 hasAuthorship W2791640892A5043416120 @default.
• W2791640892 hasAuthorship W2791640892A5054830306 @default.
• W2791640892 hasAuthorship W2791640892A5063965210 @default.
• W2791640892 hasBestOaLocation W27916408921 @default.
• W2791640892 hasConcept C104826730 @default.
• W2791640892 hasConcept C104849204 @default.
• W2791640892 hasConcept C126322002 @default.
• W2791640892 hasConcept C164705383 @default.
• W2791640892 hasConcept C170493617 @default.
• W2791640892 hasConcept C181199279 @default.
• W2791640892 hasConcept C185592680 @default.
• W2791640892 hasConcept C2775915353 @default.
• W2791640892 hasConcept C2775999527 @default.
• W2791640892 hasConcept C2776754050 @default.
• W2791640892 hasConcept C2777387769 @default.
• W2791640892 hasConcept C2778198053 @default.
• W2791640892 hasConcept C2779537366 @default.
• W2791640892 hasConcept C2781197716 @default.
• W2791640892 hasConcept C2908929049 @default.
• W2791640892 hasConcept C55493867 @default.
• W2791640892 hasConcept C71924100 @default.
• W2791640892 hasConcept C78085059 @default.
• W2791640892 hasConcept C84393581 @default.
• W2791640892 hasConceptScore W2791640892C104826730 @default.
• W2791640892 hasConceptScore W2791640892C104849204 @default.
• W2791640892 hasConceptScore W2791640892C126322002 @default.
• W2791640892 hasConceptScore W2791640892C164705383 @default.
• W2791640892 hasConceptScore W2791640892C170493617 @default.
• W2791640892 hasConceptScore W2791640892C181199279 @default.
• W2791640892 hasConceptScore W2791640892C185592680 @default.
• W2791640892 hasConceptScore W2791640892C2775915353 @default.
• W2791640892 hasConceptScore W2791640892C2775999527 @default.
• W2791640892 hasConceptScore W2791640892C2776754050 @default.
• W2791640892 hasConceptScore W2791640892C2777387769 @default.

• next